Differential sensitivity in cell lines to photodynamic therapy in combination with ABCG2 inhibition

Journal of Photochemistry and Photobiology B: Biology

Volumn 126, Issue , 2013, Pages 87-96

  Barron, Gemma A ^a   Moseley, Harry ^a   Woods, Julie A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

ABCG2; Aminolaevulinic acid; Chemo sensitivity; Ko 143; Photodynamic therapy; Protoporphyrin IX

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; BREAST CANCER RESISTANCE PROTEIN; NEUTRAL RED; PROTOPORPHYRIN;

ARTICLE; CANCER CELL CULTURE; CELL KILLING; CHEMOSENSITIVITY; CLINICAL EFFECTIVENESS; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IRRADIATION; KERATINOCYTE; NEUROBLASTOMA CELL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ABCG2; AMINOLAEVULINIC ACID; CHEMO SENSITIVITY; KO-143; PHOTODYNAMIC THERAPY; PROTOPORPHYRIN IX;

ADENOSINE; AMINOLEVULINIC ACID; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; ESTERS; EXTRACELLULAR SPACE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; ISOMERISM; NEOPLASM PROTEINS; PHOTOCHEMOTHERAPY; PROTOPORPHYRINS;

EID: 84885202666     PISSN: 10111344     EISSN: 18732682     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2013.07.003     Document Type: Article

References (54)

1. T.J. Dougherty, C.J. Gomer, B.W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan, Q. Peng, Photodynamic therapy, J. Natl. Cancer Inst. 90 (1998) 889-905.
2. P. Agostinis, K. Berg, K.A. Cengel, T.H. Foster, A.W. Girotti, S.O. Gollnick, S.M. Hahn, M.R. Hamblin, A. Juzeniene, D. Kessel, M. Korbelik, J. Moan, P. Mroz, D. Nowis, J. Piette, B.C. Wilson, J. Golab, Photodynamic therapy of cancer: an update, Ca-Cancer J. Clin. 61 (2011) 250-281.
3. H. Moseley, S. Ibbotson, J. Woods, L. Brancaleon, A. Lesar, C. Goodman, J. Ferguson, Clinical and research applications of photodynamic therapy in dermatology: experience of the Scottish PDT centre, Lasers Surg. Med. 38 (2006) 403-416.
4. C.A. Morton, K.E. McKenna, L.E. Rhodes, B.A.D. Thera, Guidelines for topical photodynamic therapy: update, Br. J. Dermatol. 159 (2008) 1245-1266.
5. S.H. Ibbotson, An overview of topical photodynamic therapy in dermatology, Photodiagnosis Photodyn. Ther. 7 (2010) 16-23.
6. D. Fayter, M. Corbett, M. Heirs, D. Fox, A. Eastwood, A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin, Health Technol. Assess 14 (2010) 1-288.
7. M.S. Eljamel, C. Goodman, H. Moseley, ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial, Lasers Med. Sci. 23 (2008) 361-367.
8. S.H. Ibbotson, R. Valentine, R. Hearn, Is the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5- aminolaevulinic acid?, Photodermatol Photoimmunol. Photomed. 28 (2012) 272-273.
9. S.H. Ibbotson, J. Ferguson, Ambulatory photodynamic therapy using low irradiance inorganic light-emitting diodes for the treatment of non-melanoma skin cancer: an open study, Photodermatol. Photoimmunol. Photomed. 28 (2012) 235-239.
10. K. Berg, H. Anholt, O. Bech, J. Moan, The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells, Br. J. Cancer 74 (1996) 688-697.
11. A. Pye, S. Campbell, A. Curnow, Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma, J. Cancer Res. Clin. Oncol. 134 (2008) 841-849.
12. E. Blake, J. Allen, A. Curnow, An in vitro comparison of the effects of the ironchelating agents, CP94 and dexrazoxane, on protoporphyrin IX accumulation for photodynamic therapy and/or fluorescence guided resection, Photochem. Photobiol. 87 (2011) 1419-1426.
13. K. Choudry, R.C. Brooke, W. Farrar, L.E. Rhodes, The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5- aminolaevulinic acid photodynamic therapy, Br. J. Dermatol. 149 (2003) 124-130.
14. S.M. Campbell, C.A. Morton, R. Alyahya, S. Horton, A. Pye, A. Curnow, Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma, Br. J. Dermatol. 159 (2008) 387-393.
15. J.W. Jonker, M. Buitelaar, E. Wagenaar, M.A. Van Der Valk, G.L. Scheffer, R.J. Scheper, T. Plosch, F. Kuipers, R.P. Elferink, H. Rosing, J.H. Beijnen, A.H. Schinkel, The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria, Proc. Natl. Acad. Sci. USA 99 (2002) 15649-15654.
16. R.W. Robey, K. Steadman, O. Polgar, S.E. Bates, ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy, Cancer Biol. Ther. 4 (2005) 187-194.
17. J.W. Jonker, S. Musters, M.L. Vlaming, T. Plosch, K.E. Gooijert, M.J. Hillebrand, H. Rosing, J.H. Beijnen, H.J. Verkade, A.H. Schinkel, Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX, Am. J. Physiol. Cell Physiol. 292 (2007) C2204-C2212.
18. G.L. Scheffer, M. Maliepaard, A.C. Pijnenborg, M.A. van Gastelen, M.C. de Jong, A.B. Schroeijers, D.M. van der Kolk, J.D. Allen, D.D. Ross, P. van der Valk, W.S. Dalton, J.H. Schellens, R.J. Scheper, Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines, Cancer Res. 60 (2000) 2589-2593.
19. E. Rocchi, A. Khodjakov, E.L. Volk, C.H. Yang, T. Litman, S.E. Bates, E. Schneider, The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane, Biochem. Biophys. Res. Commun. 271 (2000) 42-46.
20. M. Maliepaard, G.L. Scheffer, I.F. Faneyte, M.A. van Gastelen, A.C. Pijnenborg, A.H. Schinkel, M.J. van De Vijver, R.J. Scheper, J.H. Schellens, Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues, Cancer Res. 61 (2001) 3458-3464.
21. M. Solazzo, O. Fantappie, M. D'Amico, C. Sassoli, A. Tani, G. Cipriani, C. Bogani, L. Formigli, R. Mazzanti, Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines, Cancer Res. 69 (2009) 7235-7242.
22. H. Kobuchi, K. Moriya, T. Ogino, H. Fujita, K. Inoue, T. Shuin, T. Yasuda, K. Utsumi, T. Utsumi, Mitochondrial localization of ABC transporter ABCG2 and its function in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation, PLoS One 7 (2012) e50082.
23. A. Rajagopal, S.M. Simon, Subcellular localization and activity of multidrug resistance proteins, Mol. Biol. Cell 14 (2003) 3389-3399.
24. S. Aust, P. Obrist, W. Jaeger, M. Klimpfinger, G. Tucek, F. Wrba, E. Penner, T. Thalhammer, Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium, Lab. Invest. 84 (2004) 1024-1036.
25. I. Ifergan, G.L. Scheffer, Y.G. Assaraf, Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance, Cancer Res. 65 (2005) 10952-10958.
26. L.A. Doyle, W. Yang, L.V. Abruzzo, T. Krogmann, Y. Gao, A.K. Rishi, D.D. Ross, A multidrug resistance transporter from human MCF-7 breast cancer cells, Proc. Natl. Acad. Sci. USA 95 (1998) 15665-15670.
27. M.M. Gottesman, T. Fojo, S.E. Bates, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat. Rev. Cancer 2 (2002) 48-58.
28. P. Krishnamurthy, J.D. Schuetz, The ABC transporter Abcg2/Bcrp: role in hypoxia mediated survival, Biometals 18 (2005) 349-358.
29. K. Natarajan, Y. Xie, M.R. Baer, D.D. Ross, Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance, Biochem. Pharmacol. 83 (2012) 1084-1103.
30. J.E. Diestra, G.L. Scheffer, I. Catala, M. Maliepaard, J.H. Schellens, R.J. Scheper, J.R. Germa-Lluch, M.A. Izquierdo, Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material, J. Pathol. 198 (2002) 213-219.
31. S. Zhou, Y. Zong, P.A. Ney, G. Nair, C.F. Stewart, B.P. Sorrentino, Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels, Blood 105 (2005) 2571-2576.
32. S.K. Rabindran, H. He, M. Singh, E. Brown, K.I. Collins, T. Annable, L.M. Greenberger, Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C, Cancer Res. 58 (1998) 5850-5858.
33. T. Hiraga, S. Ito, H. Nakamura, Side population in MDA-MB-231 human breast cancer cells exhibits cancer stem cell-like properties without higher bonemetastatic potential, Oncol. Rep. 25 (2011) 289-296.
34. T. Ogino, H. Kobuchi, K. Munetomo, H. Fujita, M. Yamamoto, T. Utsumi, K. Inoue, T. Shuin, J. Sasaki, M. Inoue, K. Utsumi, Serum-dependent export of protoporphyrin IX by ATP-binding cassette transporter G2 in T24 cells, Mol. Cell Biochem. 358 (2011) 297-307.
35. A. Bebes, T. Nagy, Z. Bata-Csorgo, L. Kemeny, A. Dobozy, M. Szell, Specific inhibition of the ABCG2 transporter could improve the efficacy of photodynamic therapy, J. Photochem. Photobiol. B 105 (2011) 162-166.
36. T. Asashima, S. Hori, S. Ohtsuki, M. Tachikawa, M. Watanabe, C. Mukai, S. Kitagaki, N. Miyakoshi, T. Terasaki, ATP-binding cassette transporter G2 mediates the efflux of phototoxins on the luminal membrane of retinal capillary endothelial cells, Pharm. Res. 23 (2006) 1235-1242.
37. W. Liu, M.R. Baer, M.J. Bowman, P. Pera, X. Zheng, J. Morgan, R.A. Pandey, A.R. Oseroff, The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2, Clin. Cancer Res. 13 (2007) 2463-2470.
38. A. Tamura, K. Wakabayashi, Y. Onishi, M. Takeda, Y. Ikegami, S. Sawada, M. Tsuji, Y. Matsuda, T. Ishikawa, Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2, Cancer Sci. 98 (2007) 231-239.
39. A. Tamura, Y. Onishi, R. An, S. Koshiba, K. Wakabayashi, K. Hoshijima, W. Priebe, T. Yoshida, S. Kometani, T. Matsubara, K. Mikuriya, T. Ishikawa, In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs, Drug Metab. Pharmacokinet 22 (2007) 428-440.
40. S. Piomelli, A micromethod for free erythrocyte porphyrins: the FEP test, J. Lab. Clin. Med. 81 (1973) 932-940.
41. A.C. Deacon, G.H. Elder, ACP best practice no. 165: front line tests for the investigation of suspected porphyria, J. Clin. Pathol. 54 (2001) 500-507.
42. C.K. Lim, T.J. Peters, Urine and faecal porphyrin profiles by reversed-phase high-performance liquid chromatography in the porphyrias, Clin. Chim. Acta 139 (1984) 55-63.
43. N.J. Traynor, M.D. Barratt, W.W. Lovell, J. Ferguson, N.K. Gibbs, Comparison of an in vitro cellular phototoxicity model against controlled clinical trials of fluoroquinolone skin phototoxicity, Toxicol. In Vitro 14 (2000) 275-283.
44. A. Kerr, J. Woods, J. Ferguson, Photocontact allergic and phototoxic studies of chlorproethazine, Photodermatol. Photoimmunol. Photomed. 24 (2008) 11-15.
45. Z. Ji, G. Yang, V. Vasovic, B. Cunderlikova, Z. Suo, J.M. Nesland, Q. Peng, Subcellular localization pattern of protoporphyrin IX is an important determinant for its photodynamic efficiency of human carcinoma and normal cell lines, J. Photochem. Photobiol. B 84 (2006) 213-220.
46. L.N. Milla, I.S. Cogno, M.E. Rodriguez, F. Sanz-Rodriguez, A. Zamarron, Y. Gilaberte, E. Carrasco, V.A. Rivarola, A. Juarranz, Isolation and characterization of squamous carcinoma cells resistant to photodynamic therapy, J. Cell Biochem. 112 (2011) 2266-2278.
47. T. Kriska, W. Korytowski, A.W. Girotti, Role of mitochondrial cardiolipin peroxidation in apoptotic photokilling of 5-aminolevulinate-treated tumor cells, Arch. Biochem. Biophys. 433 (2005) 435-446.
48. X. Chen, P. Zhao, F. Chen, L. Li, R. Luo, Effect and mechanism of 5- aminolevulinic acid-mediated photodynamic therapy in esophageal cancer, Lasers Med. Sci. 26 (2011) 69-78.
49. S. Sharma, A. Jajoo, A. Dube, 5-Aminolevulinic acid-induced protoporphyrin-IX accumulation and associated phototoxicity in macrophages and oral cancer cell lines, J. Photochem. Photobiol. B 88 (2007) 156-162.
50. L. Brancaleon, S.W. Magennis, I.D. Samuel, E. Namdas, A. Lesar, H. Moseley, Characterization of the photoproducts of protoporphyrin IX bound to human serum albumin and immunoglobulin G, Biophys. Chem. 109 (2004) 351-360.
51. J.M. Gaullier, K. Berg, Q. Peng, H. Anholt, P.K. Selbo, L.W. Ma, J. Moan, Use of 5- aminolevulinic acid esters to improve photodynamic therapy on cells in culture, Cancer Res. 57 (1997) 1481-1486.
52. W. Dietel, K. Bolsen, E. Dickson, C. Fritsch, R. Pottier, R. Wendenburg, Formation of water-soluble porphyrins and protoporphyrin IX in 5- aminolevulinic-acid-incubated carcinoma cells, J. Photochem. Photobiol. B 33 (1996) 225-231.
53. M. Hefti, F. Holenstein, I. Albert, H. Looser, V. Luginbuehl, Susceptibility to 5- aminolevulinic acid based photodynamic therapy in WHO I meningioma cells corresponds to ferrochelatase activity, Photochem. Photobiol. 87 (2011) 235-241.
54. G. Di Venosa, H. Fukuda, A. Batlle, A. Macrobert, A. Casas, Photodynamic therapy: regulation of porphyrin synthesis and hydrolysis from ALA esters, J. Photochem. Photobiol. B 83 (2006) 129-136.